<?xml version="1.0" encoding="UTF-8"?>
<ref id="B24">
 <label>24</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Zhang</surname>
    <given-names>W</given-names>
   </name>
   <name>
    <surname>Shen</surname>
    <given-names>Z</given-names>
   </name>
   <name>
    <surname>Luo</surname>
    <given-names>H</given-names>
   </name>
   <name>
    <surname>Hu</surname>
    <given-names>X</given-names>
   </name>
   <name>
    <surname>Zheng</surname>
    <given-names>L</given-names>
   </name>
   <name>
    <surname>Zhu</surname>
    <given-names>X</given-names>
   </name>
  </person-group>. 
  <article-title>The Benefits and Side Effects of Bevacizumab for the Treatment of Recurrent Ovarian Cancer</article-title>. 
  <source>Curr Drug Targets</source> (
  <year>2017</year>) 
  <volume>18</volume>:
  <page-range>1125–31</page-range>.  
  <pub-id pub-id-type="doi">10.2174/1389450117666160502150237</pub-id>
 </mixed-citation>
</ref>
